SIFI receives Marketing Authorisation and Promising Innovative Medicine Designation for AKANTIOR® in the UK

SIFI S.p.A. Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America

MHRA granted on 6th May the Promising Innovative Medicine (PIM) DesignationMHRA granted on 15th May the Marketing Authorisation, confirming the Orphan Drug Designation and the New Active Substance status View original content:https://www.prnewswire.co.uk/news-releases/sifi-receives-marketing-authorisation-and-promising-innovative-medicine-designation-for-akantior-in-the-uk-302458363.html